Table 5.
Observed averaged number of patients under the null and alternative hypotheses for erlotinib resistant and naïve patients by marker status in the BATTLE-2 design
| Under Null Hypothesis
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Markers | Erlotinib Naïve | Erlotinib Resistant | ||||||
|
| ||||||||
| M1 | M2 | TX1 | TX2 | TX3 | TX4 | TX2 | TX3 | TX4 |
|
| ||||||||
| − | − | 15.2 | 14.0 | 14.5 | 13.3 | 14.9 | 15.6 | 14.6 |
| + | − | 3.9 | 3.9 | 3.3 | 3.4 | 3.7 | 3.5 | 4.1 |
| − | + | 2.9 | 5.1 | 3.6 | 2.8 | 4.5 | 3.7 | 2.9 |
| + | + | 0.8 | 1.1 | 0.8 | 0.8 | 1.0 | 0.9 | 0.9 |
|
| ||||||||
| Under Alternative Hypothesis | ||||||||
|
| ||||||||
| Markers | Erlotinib Naïve | Erlotinib Resistant | ||||||
|
| ||||||||
| M1 | M2 | TX1 | TX2 | TX3 | TX4 | TX2 | TX3 | TX4 |
| − | − | 10.0 | 15.9 | 15.9 | 15.7 | 14.8 | 14.8 | 15.4 |
| + | − | 3.3 | 4.1 | 3.6 | 3.4 | 4.0 | 3.8 | 3.5 |
| − | + | 2.1 | 4.9 | 3.3 | 4.0 | 3.9 | 3.2 | 4.0 |
| + | + | 0.7 | 1.1 | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |